Word: rheumatoid
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...Artist in Winter In the late 1890s, renoir developed rheumatoid arthritis. It progressed until his fingers were bent into claws, the tips pressed against the palms of his hands. On the recommendation of his doctors, he moved from Paris to the dry climate of Provence, where, like so many other artists, he found a personal paradise, a garden tended by ghosts of the ancient Mediterranean. His was a farmstead in Cagnes-sur-Mer, not far from Nice. Though in constant pain, Renoir entered the most productive period of his career, producing hundreds of canvases, many of them painted while...
...biotechnology medicines in development last year for more than 100 diseases, half the new drugs approved in 2015 will be. Biologics average more than 20 times the cost of traditional drugs: treating breast cancer with a year's worth of the biologic Herceptin can cost $48,000; Remicade, for rheumatoid arthritis, can cost $20,000 annually. For other, rarer diseases, the price of biologic treatments can be as high as $200,000 a year...
...Harvard Medical School professor accused of plagiarizing a review of rheumatoid arthritis treatments turned in his resignation last week, over a year after the alleged infraction. The allegedly offending professor, Lee S. Simon, had his article in the biomedical journal “Best Practices & Research: Clinical Rheumatology” retracted last year. The retraction came after a data-comparison search engine found that about half the text of the article was taken verbatim from a paper published in 2003. Though he had not spoken directly with Simon about the matter, Simon M. Helfgott, a rheumatologist at Brigham and Women?...
Hacohen’s research focuses on determining how immune responses are triggered under different conditions, including infections and for autoimmune reactions, such as organ transplant rejection or rheumatoid arthritis...
...also grant older medications a new lease on life. Take the cancer drug MabThera, sold in the U.S. as Rituxan. MabThera was originally developed to treat non-Hodgkin's lymphoma. In 2006, Roche scientists noticed--again using biomarkers--that it was also extremely effective in certain cases of rheumatoid arthritis, a painful autoimmune condition that causes joint inflammation. Roche's sales to arthritis patients have already totaled more than $420 million...